Trial Profile

A clinical trial assessing EV-104

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 14 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EV-104 (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Sponsors EvolveImmune Therapeutics

Most Recent Events

11 Feb 2025 According to EvolveImmune Therapeutics media release, the company is planning to enter into the clinic by mid-2025.
18 Nov 2022 New trial record
10 Nov 2022 According to EvolveImmune Therapeutics media release, the company look forward to progressing EV-104 into the clinic by early 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com